In January 2026, the World Health Organization (WHO) updated its Model List of Essential Medicines, which now includes over 520 medicines, reflecting the evolving global health priorities. (who.int) Although Ambroxol was not added, this update underscores the dynamic nature of essential medicine classifications.
In February 2026, the WHO published the 25th report of the Expert Committee on Selection and Use of Essential Medicines, providing insights into the criteria and considerations for medicine selection. (who.int) This report serves as a valuable resource for manufacturers and exporters aiming to align their products with global health standards.
In March 2026, the WHO released a list of National Regulatory Authorities operating at maturity levels 3 and 4, indicating robust regulatory systems. (who.int) This development highlights the importance of compliance with stringent regulatory standards for market access.
In April 2025, the WHO unveiled a global repository for National Essential Medicines Lists (nEMLs), facilitating access to information on essential medicines across countries. (who.int) This initiative aids exporters in understanding market-specific requirements and aligning their portfolios accordingly.
In May 2025, the WHO's Expert Committee on Selection and Use of Essential Medicines convened to review and update the Model Lists, reflecting ongoing efforts to address global health needs. (who.int) Such updates are crucial for manufacturers to stay informed about potential changes affecting their product offerings.
These developments underscore the importance of staying abreast of regulatory changes and global health priorities to ensure compliance and strategic alignment in the pharmaceutical export sector.
